DrugPatentWatch Database Preview
Larotrectinib - Generic Drug Details
» See Plans and Pricing
Summary for larotrectinib
International Patents: | 129 |
US Patents: | 10 |
Tradenames: | 1 |
Applicants: | 2 |
NDAs: | 2 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 20 |
Clinical Trials: | 2 |
Patent Applications: | 30 |
DailyMed Link: | larotrectinib at DailyMed |
Recent Clinical Trials for larotrectinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nationwide Children's Hospital | Early Phase 1 |
Children's Oncology Group | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for larotrectinib
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |